Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study

Retrospective exploratory analysis of TP53-mutant ctDNA as a treatment-response biomarker in relapsed high-grade serous ovarian carcinoma.

PLoS MedPubMed 27997533DOI 10.1371/journal.pmed.1002198